Young Kwang Chae

  • 1509 Citations
20072021
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Personalized Cancer Therapy, Precision Medicine, Early Phase Clinical Trials, First-in-Human Study, Novel Combination Cancer Therapy, Targeted therapy, Immunotherapy, Biomarker Study, Novel Drug Development, Novel Drug Delivery System, Adaptive Clinical Trials Design, Cell Signaling Pathway, Immune Checkpoint Pathway

Training Experience

2011Residency, Albert Einstein Medical Center
2014Fellowship, University of Texas/MD Anderson Cancer Center

Education/Academic qualification

MBA, Johns Hopkins University

… → 2007

MPH, Johns Hopkins University

… → 2007

MD, Seoul National University

… → 2002

Keywords

  • Oncology

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 7 Similar Profiles
Neoplasms Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Hydroxymethylglutaryl-CoA Reductase Inhibitors Medicine & Life Sciences
Biomarkers Medicine & Life Sciences
T-Lymphocytes Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2013 2021

Research Output 2007 2019

A phase I dose-escalation study of veliparib combined with carboplatin and etoposide in patients with extensive-stage small cell lung cancer and other solid tumors

Atrafi, F., Groen, H. J. M., Byers, L. A., Garralda, E., Lolkema, M. P., Sangha, R. S., Viteri, S., Chae, Y. K., Ross Camidge, D., Gabrail, N. Y., Hu, B., Tian, T., Nuthalapati, S., Hoening, E., He, L., Komarnitsky, P. & Calles, A., Jan 15 2019, In : Clinical Cancer Research. 25, 2, p. 496-505 10 p.

Research output: Contribution to journalArticle

Open Access
Carboplatin
Small Cell Lung Carcinoma
Etoposide
Neoplasms
Disease Progression

Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti–PD-1/PD-L1 Therapy in Non–Small-Cell Lung Cancer

Chae, Y. K., Davis, A. A., Raparia, K., Agte, S., Pan, A., Mohindra, N. A., Villaflor, V. M. & Giles, F., Mar 1 2019, In : Clinical Lung Cancer. 20, 2, p. 88-96.e6

Research output: Contribution to journalArticle

Tumor Burden
Non-Small Cell Lung Carcinoma
DNA Repair
Ligands
Mutation
DNA Mismatch Repair
Endometrial Neoplasms
Immunotherapy
Ligands
Neoplasms

Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes

Tray, N., Taff, J., Singh, B., Suh, J., Ngo, N., Kwa, M., Troxel, A. B., Chae, Y. K., Kurzrock, R., Patel, S. P., Sharon, E., Denkert, C., Ross, J. S. & Adams, S., Apr 1 2019, In : Breast. 44, p. 29-32 4 p.

Research output: Contribution to journalArticle

Tumor-Infiltrating Lymphocytes
Breast Neoplasms
Triple Negative Breast Neoplasms
Biomarkers
Drug Therapy

Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma

Chae, Y. K., Anker, J. F., Oh, M. S., Bais, P., Namburi, S., Agte, S., Giles, F. J. & Chuang, J. H., Dec 1 2019, In : Scientific Reports. 9, 1, 3235.

Research output: Contribution to journalArticle

Open Access
DNA Repair
Squamous Cell Carcinoma
Lung
Mutation
Genes